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Aims: A growing body of evidence shows the cardiovascular beneﬁts of ﬁsh oil ingredients, including
eicosapentaenoic acid (EPA), in humans and experimental animals. However, the effects of EPA on endothelin
(ET)-1-induced cardiomyocyte hypertrophy and the involved signaling cascade are largely unknown. A previous
study has demonstrated that peroxisomal proliferator-activated receptor (PPAR)-α ligand (fenoﬁbrate) prevents
ET-1-induced cardiomyocyte hypertrophy. Although EPA is a ligand of PPAR-α, to date, no study has examined a
relationship between EPA and PPAR-α in cardiomyocyte hypertrophy. Here, we investigated whether EPA can
block ET-1-induced cardiomyocyte hypertrophy and the possible underlying mechanisms.
Main methods: At day 4 of culture, neonatal rat cardiomyocytes were divided into four groups: control, control
cells treatedwith EPA (10 μM), ET-1 (0.1 nM) administered only and EPA-pre-treated ET-1 administered groups.
Also, the cardiomyocytes were treated with PPAR-α siRNA in order to elucidate the mechanisms that may
underlie suppression of hypertrophy via the EPA-PPAR system.
Key ﬁndings: Following ET-1 treatment, 2.12- and 1.92-fold increases in surface area and total protein synthesis
rate in cardiomyocytes, respectively, were observed and these changes were greatly blocked by EPA pre-
treatment. Further, the expression of PPAR-α increased in EPA-treated groups. PPAR-PPRE binding activity was
suppressed in ET-1 administered cardiomyocyte and this suppression was improved by EPA treatment. Lastly,
pre-treatment of cardiomyocytes with PPAR-α siRNA prior to EPA treatment attenuated the suppressing effects
of EPA on cardiomyocyte hypertrophy.
Signiﬁcance: In conclusion, the present study shows that EPA attenuates ET-1 induced cardiomyocyte hyper-
trophy by up regulating levels of PPAR-α pathway.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Cardiac hypertrophy is a major predictor of progressive heart
disease, an indicator of a poor prognosis (Rohini et al., 2010), as well
as constitutes an independent risk factor for heart failure, hypertension
and ischemic heart disease (Sadoshima et al., 1992; Rohini et al., 2010;
Ho et al., 1998). In general, pathological hypertrophy occurs in response
to aberrant stress signals, e.g. neuro-hormonal activation, aorticitical Care Medicine, Faculty of
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. This is an open access article understenosis, inﬂammation or cardiac injury (Rohini et al., 2010). Speciﬁcal-
ly, one of the most important vascular hormones that contribute to the
development of hypertrophy is endothelin (ET)-1. The ET system is
comprised of 3 active ETs, i.e., ET-1-3 (Yanagisawa et al., 1988;
Giannessi et al., 2001). ET-1, themain isoform, is synthesized inmultiple
cell types, including endothelial,muscular coat of arterialwall, aswell as
in the heart, kidney and central nervous system (Yanagisawa et al.,
1988). The actions of ET are mediated through its interaction with two
classes of cell surface receptors, namely ET type A (ETA) and ET type B
(ETB). ETA receptor mediates vasoconstriction and cell growth, whereas
ETB receptor is linked to endothelial-cell mediated vasodilatation and
release of other neuro-hormones, such as aldosterone (Giannessi et al.,
2001). In vitro studies have shown that ET-1-induced cardiac hyper-
trophy involves various signaling cascades mediated by ETA receptors,
such as Raf-1 and mitogen-activated protein kinases in the neonatal
rat (Shimojo et al., 2006; Yamazaki et al., 1996). Other signaling
pathways mediating ET-1-induced cardiac hypertrophy includethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
174 N. Shimojo et al. / Life Sciences 118 (2014) 173–178phospholipase C, PKC, ERK1 and ERK2, c-Fos and c-Jun, c-Jun NH2-
terminal kinase (JNK) and p38 (Irukayama-Tomobe et al., 2004;
Shimojo et al., 2006).
Recent studies show strong and compelling evidence that con-
sumption of ﬁsh-derived fatty acids, such as eicosapentaenoic acid
(EPA) (20:5n-3) and docosahexaenoic acid (DHA) (22:6n-3), provide
cardioprotective beneﬁts. Speciﬁcally, these fatty acids (EPA and DHA)
alter membrane ﬂuidity, interact with transcription factors, such as
peroxisomal proliferator-activated receptor (PPAR) and sterol regulato-
ry element binding protein (Krey et al., 1997), and are substrates for
enzymes, including cyclooxygenase, lipoxygenase and cytochrome
P450 (Cottin et al., 2011). In the late 1990s, EPA, as well as other ω-3
polyunsaturated fatty acid (PUFA), was ﬁrst described as a ligand of
PPAR (Krey et al., 1997), which (PPAR) has three isoforms, namely α,
β/δ, and γ, and belongs to a superfamily of nuclear hormone receptors
of the heart. PPAR is also activated by a diverse group of ligands, in-
cluding unsaturated fatty acids and isoforms of speciﬁc drugs, such as
ﬁbrates (PPAR-α) and anti-diabetic drugs of thiazolidinediones class
(PPAR-γ) (Planavila et al., 2005). PPAR-α, the predominant PPAR
isoform in the heart, has been implicated in hypertrophic signaling.
PPAR-α activator, fenoﬁbrate, interferes with the signaling pathway of
ET-1-induced cardiac hypertrophy through negative regulation of
activator protein-1 (AP-1) binding activity, partly via inhibition of the
JNK pathway in cultured cardiomyocytes (Irukayama-Tomobe et al.,
2004). However, it is unclear whether EPA-activated PPAR-α can
ameliorate cardiomyocyte hypertrophy.
The present study investigated whether activation of the PPAR-α
pathway mediates the suppressive effects of EPA in ET-1-induced
hypertrophy of cardiomyocytes.Materials and methods
Myocyte isolation and culture
Ventricular cardiac myocytes were isolated from 2- to 3-day-old
Sprague-Dawley rats, as described previously (Shimojo et al., 2006),
and were incubated on ﬁbronectin-coated dishes in DMEM-Ham's F-
12 medium supplemented with 0.1% fatty acid-free BSA (Sigma,
St. Louis, MO). Cells were then cultured for 3 days after differential
adhesion and later used for further experiments. Initially, myocytes
were only exposed to vehicle prior to treatments (control, in 95% air-
5% CO2), and at day 4, the cardiomyocytes were treated either with
10 μM EPA, 0.1 nM ET-1 or pre-treated with 10 μM EPA, followed by
0.1 nM ET-1 on day 5 of culture for 24 h and harvested for analysis. In
order to determine the optimal doses of ET-1 and EPA, dose response
studies were performed, as described here: 1) ET doses: a) 10−8, b) 10
−9, c) 10−10 and d) 10−11 M and 2) EPA doses: a) 1, b) 3, c) 10, d) 30
and e) 100 μM (Shimojo et al., 2006). All animal experiments were
carried out in a humane manner and were pre-approved by the
local Institutional Animal Experiment Committee of the University of
Tsukuba.Cardiomyocyte surface area
In order to determine changes in cell size, images of cells were
captured using a charge-coupled device camera (Olympus, Tokyo,
Japan) and the peripheries of the cells were traced and analyzed on
the captured images using the NIH Image software (National Institutes
of Health, Bethesda, MD). These values were then doubled to account
for the portion of the cell surface in contact with the dish. All cells
from randomly selected ﬁelds in two or three dishes were examined
for each experimental group. A total of 100 cells in each experimental
group were examined, as described in our previous study (Shimojo
et al., 2006, 2007).Protein synthesis
The effects of various treatments on the rate of protein synthesis in
cardiomyocytes were investigated, as described previously (Shimojo
et al., 2006). Brieﬂy, protein synthesis in cultured neonatal rat ventricu-
larmyocytes was evaluated bymeasuring incorporation of [14C] leucine
into acid-insoluble cellular material. The cells were plated in 24-well
dishes at a density of 105 cells/well. After treatmentwith ET-1 or vehicle
for 24 h, 0.1 μCi/ml [14C] leucinewas added and cells were incubated for
24 h. The cells werewashed twicewith cold PBS, and 5% TCAwas added
for 10min. The cells were then incubatedwith 0.25% trypsin at 37 °C for
30 min, and cell residues were solubilized in 0.5 N NaOH for 10 min.
Aliquots were then counted with a scintillation counter (Beckman LS-
6500 scintillation counter; Beckman Coulter, Fullerton, CA).
Western blot analysis
Cardiomyocyteswere plated at a ﬁeld density of 2 × 106 cells/cm2 on
60-mm culture dishes with 2 ml of culture medium. Cardiomyocytes
from the different treatment groups were lysed on ice with buffer
(10 mM Tris · HCl, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.1%
sodium deoxycholate and 0.1% SDS). The protein concentration of the
supernatant was determined using the bicinchoninic acid protein
assay (Pierce, Rockford, IL). Samples were run on SDS-PAGE,
using 7.5–10% polyacrylamide gel, and electrotransferred to poly-
vinylidenediﬂouride (PVDF) ﬁlter membrane. To reduce non-speciﬁc
binding, the PVDFmembrane was blocked for 2 h at room temperature
with 5% non-fat milk in PBS containing 0.1% Tween 20 (TPBS). Thereaf-
ter, the PVDF membrane was incubated overnight at 4 °C with primary
antibodies in TPBS. After washing the membrane three times in TPBS,
we incubated it in horseradish peroxidase-conjugated anti-rabbit
(Amersham Biosciences UK, Little Chalfont, Buckinghamshire, UK),
anti-mouse (Amersham Biosciences), or anti-goat antibodies (Santa
Cruz Biotechnology, Dallas, TX), diluted at 1:2,000–10,000 in TPBS at
room temperature for 60 min. The blots were visualized with an
enhanced chemiluminescence detection system (Amersham Biosci-
ences), exposed to X-ray ﬁlm, and analyzed by free NIH Image software
produced by Wayne Rasband (National Institutes of Health). Only
negligible loading or transfer variations were observed between
samples.
Commercial rabbit polyclonal PPAR-α antibody (Santa Cruz Biotech-
nology) and mouse monoclonal β-actin antibody (Abcam, Cambridge,
UK) were used.
RNA interference
Small interference RNA (siRNA) molecules were designed using
Invitorgen's website and transfected into cardiomyocytes using
Oligofectamine. A ﬂuorescein isothiocyanate-labeled non-sense siRNA
molecule was used as control. Transfected cells were recovered for 24
h and treated with/without EPA as described before. Knockdown in
gene expression was identiﬁed after isolating the RNA and performing
protein blots 48 h after expression of the siRNAs (Fig. 2). β-actin was
used as an internal control.
PPAR-α to DNA binding activity assay
The degree of DNA binding of PPAR-αwas determined by an immu-
nosorbent assay (ELISA) utilizing PPAR-α transcription factor assay kits
(Cayman Chemical, Ann Arbor, MI), according to the manufacturer's
instructions. Brieﬂy, a speciﬁc double stranded DNA sequence con-
taining the peroxisome proliferator responsive element (PPRE) was
immobilized onto the bottom of thewells of the 96-well plates. Aliquots
of harvested cells diluted to obtain 50 μg protein in each assay
were added to each well, so that PPAR contained in the extract bind
speciﬁcally to the PPRE. PPAR-αwas detected by the addition of speciﬁc
Fig. 2. Representative image of immunoblotting of PPAR-α in cardiomyocyte extracts in
presence or absence of EPA or PPAR-α siRNA. β-actin was used as internal control.
175N. Shimojo et al. / Life Sciences 118 (2014) 173–178primary antibodies directed against PPAR-α. A secondary antibody
conjugated to HRP was added to provide a sensitive colorimetric
readout at 450 nm.
Statistical analysis
Values for data generated in the present study were expressed as
means ± SE. Intergroup differences were compared using one-way
ANOVA, adjusted by Bonferroni's using the IBM-SPSS version 19.0
software (IBM-SPSS Inc, Chicago, IL). The same total number of sample
size for each experimental group was determined as reported in our
previous study (Shimojo et al., 2006, 2007). Differences were consid-
ered signiﬁcant at p b 0.05.
Results
In our current experimental design, we determined PPAR-α expres-
sion in four experimental groups. Here,we showadifferential expression
of PPAR-a, based on four different treatments (Fig. 1). Speciﬁcally, we
show that PPAR-α expression was signiﬁcantly up regulated in EPA
pre-treated groups, as determined by immunoblotting, irrespective of
ET-1 administration. Notably, a marked increase of PPAR-α expression
was observed in the EPA pre-treated group that was later administered
with ET-1 than the group (EPA) without ET-1. Interestingly, the expres-
sion of PPAR-α was signiﬁcantly down-regulated in ET-1-induced
hypertrophied cardiomyocytes compared to control (Fig. 1A). Similar
types of results were obtained from DNA-binding assay when evaluatingFig. 1. Typical Western blot and intensity of the bands of PPAR-α of control (Con), EPA-
treated (Con + EPA) control cells, ET-1-treated (ET-1) only, and EPA-pretreated ET-1-
administred (EPA + ET-1) cardiomyocytes (A). In each experiment, Con value is
normalized as 1.0. Values are means ± SE of 5–7 separate experiments. DNA binding
activity of PPAR-α determined by an immunosorbent assay (B) in Con, Con + EPA, ET-1,
and EPA + ET-1 cardiomyocytes. Values are means ± SE. *P b 0.01 vs. Con; #P b 0.01 vs.
ET-1; ##P b 0.0001 vs. ET-1; †p b 0.05 vs. Con + EPA.PPAR-α's DNA-binding activity to the PPAR response elements (PPRE), in
both EPA pre-treated groups. PPAR-α's DNA-binding activity to PPREwas
enhanced with or without ET-1 administration (Fig. 1B).
Under the current experimental setting, the expression of PPAR-α
was down-regulated by siRNA, with or without EPA administration
in neonatal cardiomyoctes. PPAR-α expression in siRNA-transfected
cardiomyocyte was almost reduced by 80% compared to the EPA-only
treated group (Fig. 2). Thus, the same PPAR-α siRNA was used in sub-
sequent experiments.
Representative photographs of themorphological evaluation of four
experimental groupswere also obtained (Fig. 3). ET-1 caused signiﬁcant
increase in the cell surface area of cardiomyocyte (2.12 fold: p b 0.0001
vs. control) and this morphological change was greatly ameliorated
by pre-treating cells with EPA (45% decrease: p b 0.0001 vs. ET-1)
(Fig. 3B). It is important to note that no signiﬁcant morphological
change was observed between the control and EPA-only administered
cardiomyocyte groups (p = 0.93) (Fig. 3A), based on cell surface area.
Next, we examined the effects of PPAR-α siRNA on EPA pre-treated
cardiomyocytes that were later administered with ET-1, which induced
hypertrophy. Pre-treatment of the EPA + ET-1-administered group
with the siRNA of PPAR-α signiﬁcantly inhibited the EPA-mediated
anti-hypertrophic action in ET-1-induced hypertrophied cardiomyocyte
(Fig. 3B). Consistent with changes observed in the cell surface area, 14C-
leucine incorporation was markedly increased in ET-1-administered
groups, and these increases were resolved by EPA pre-treatment
(Fig. 3C). Pre-treatment of EPA + ET-1-administered hypertrophied
cardiomyocytes with PPAR-α siRNA has signiﬁcantly attenuated the
regression of cardiomyocyte hypertrophy exerted by EPA treatment,
as observed in 14C-leucine incorporation (Fig. 3C).
Discussion
The novelty of the present study is the demonstration that ET-1-
induced hypertrophic remodeling in rat neonatal cardiomyocyte is
effectively prevented by the pre-treatment of cells by EPA and that the
anti-hypertrophic effects of EPA are likely mediated by PPAR-α activa-
tion. EPA treatment induced both the expression and DNA binding ac-
tivity of PPAR-α in ET-1 administered hypertrophied cardiomyocytes.
Furthermore, treatment with PPAR-α siRNA signiﬁcantly attenuated
the amelioration exerted by EPA on ET-1-induced cardiomyocyte
hypertrophy.
In the present study, we found that ET-1 induced signiﬁcant hyper-
trophy in neonatal rat cardiomyocytes. There was signiﬁcant increase
in cell size, cell surface area, as well as increased protein synthesis
rate in ET-1 administered cardiomyocytes compared to control cardio-
myocyte. The most potential ﬁnding in the present study is that pre-
treatment of cells with EPA regresses ET-1-induced cardiomyocyte
hypertrophy through the activation of PPAR-α. These current ﬁndings
are consistent with our previous report that showed that ET-1
can induce signiﬁcant hypertrophic changes in cardiomyocytes by up-
regulating levels of key hypertrophic markers (ANP and BNP)
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Fig. 3. Representative charge-coupled device camera images (A) of control (Con), EPA-treated (Con + EPA) control cells, ET-1-treated (ET-1) only, and EPA-pretreated ET-1-administred
(EPA + ET-1) cardiomyocytes. Magniﬁcation ×400. Effect of pre-treatment of PPAR-α si-RNA on EPA treated ET-1 administered cell surface area (B) and [14C]leucine uptake (C) in rat
ventricular cardiomyocytes. si-RNA transfected cells were recovered for 24 h and treatedwith/without EPA and ET-1. Data are obtained from control (untreated) cardiomyocytes are nor-
malized as 100%. Data are means ± SE; n = 100 (B) and n = 10 (C). *p b 0.05 vs. Con; **p b 0.001 vs. Con; #p b 0.05 vs. ET-1; ##p b 0.001 vs. ET-1; †p b 0.05 vs. ET-1 + EPA.
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could be effectively prevented by pre-treating cells with EPA. EPA
exerted its effects in that study by suppressing phosphorylated JNK,
and c-Jun (Shimojo et al., 2006). Phosphorylated JNK activates the
transcription factor, AP-1, which could increase ET-1 gene expression
in cardiomyocyte (Kudoh et al., 1997; Irukayama-Tomobe et al.,
2004). Such a positive feedback system of phosphorylared JNK, AP-1
and ET-1 may play crucial roles in the development of cardiomyocytehypertrophy (Fujisaki et al., 1995). On the other hand, PPARs have
been suggested to interfere negatively with levels of AP-1, Stat and
NF-κB signaling pathways by competing for essential co-factors
(Delerive et al., 1999). Therefore, activated PPAR-α is thought to bind
to AP-1 or its cofactor and that AP-1 is prevented from binding to the
cis-elements of the promoter region, which results in impairment of
ET-1 gene induction. Thus, one possible mechanism of the inhibitory
action of PPAR-α activation on ET-1-induced cardiac hypertrophy may
177N. Shimojo et al. / Life Sciences 118 (2014) 173–178be through interference of AP-1 binding to the ET-1 gene promoter
(Irukayama-Tomobe et al., 2004; Takemoto et al., 1999; Ogata et al.,
2002). Collectively, these facts led us to speculate that EPAmay interfere
in the ET-1 positive feedback system as stated above via EPA-PPAR-α-
AP-1 pathway.
Recent reportsmay shed light on themechanismunderlying the role
of activated PPAR-α in the suppression of ET-1-induced cardiomyocyte
hypertrophy. Activation of PPAR-α prevents ET-1 induced-cardiac
hypertrophy in neonatal rat cardiomyocytes through regulating
PI3K/Akt/glycogen synthase kinase (GSK)3β and nuclear factor of acti-
vated T cells (NFATc4) signaling pathway (Li et al., 2007). Le et al. also
suggest that activated PPAR-α can compete with GATA-4 binding to
NFATc4, thereby decreasing trans-activation of NFATc4, and interfering
with ET-1-induced cardiomyocyte hypertrophy (Le et al., 2012). On the
other hand, in piglet cerebral microvascular endothelial culture, it was
demonstrated that PPAR-α activation attenuated ET-1 production by
agents that mediate brain injury. The likely mechanism for such a
process could probably be mediated by the PPAR-α-induced increase
in eNOS expression/NO production and the complex PKC signaling
pathways (Yakubu et al., 2007), thus suggesting some potential beneﬁ-
cial effects in using PPAR-α agonists in addressing cardiovascular
remodeling.
ET-1 also induces NF-κB via two independent cascades (via ETA
receptor, or via diacylglycerol) in human renal tubular epithelial cells
(Gerstung et al., 2007), and NF-κB represents a key factor that mediates
both neuro-hormonal and pro-inﬂammatory signals, leading ﬁnally to
hypertrophic and/or ﬁbrotic processes in the cardiovascular system
(Takemoto et al., 1999; Pechanova and Simko, 2010). Thus, ET-1 also
induced cardiomyocyte hypertrophy via NF-κB-mediated pathways.
Further, myocardial ﬁbrosis and diastolic dysfunction in deoxy-
corticosterone acetate-salt hypertensive rats is ameliorated by PPAR-α
activator fenoﬁbrate, partly by suppressing inﬂammatory responses as-
sociated with the nuclear NF-κB pathway (Ogata et al., 2004). Thus, EPA
may also prevent ET-1-induced hypertrophy via ET-1-NF-κB pathway in
rat neonatal cardiomyocytes.
We also found here that EPA treatment, in both control and ET-1-
administered cardiomyocytes, enhanced the expression of PPAR-α
compared to either control group or ET-1 administered group only.
But the extent of PPAR-α up regulation is greater in ET-1-administered
cells than the control group after EPA treatment. In addition, PPAR-α
expression is signiﬁcantly diminished in ET-1 administered cardiomyo-
cyte hypertrophy group compared to the control cardiomyocytes. Based
on these results, we speculate that pre-treatment of cells in the control
group by EPA induced amore pronounced increase of PPAR-α than that
of ET-1-administered hypertrophied cardiomyocytes. This unexpected
effect of EPA pre-treatment regarding the expression of PPAR-α cannot
be explained in the present study. Cardiac energymetabolic shifts occur
as a normal response to diverse physiologic and dietary conditions and
as a component of the pathophysiologic processes that accompany
cardiac hypertrophy, heart failure and myocardial ischemia. The
capacity to produce energy via the utilization of fats by the mammalian
postnatal heart is controlled in part at the level of nuclear gene encoding
enzymes that are involved in mitochondrial fatty acid β-oxidation,
including PPAR-α (Barger and Kelly, 2000). In the present study, the
decrease of PPAR-α expression in ET-1-administered cardiomyocyte
group implies that ET-1 treatment caused the myocytes to turn from
aerobic to anaerobic metabolism because of mitochondrial dysfunction.
ET-1 is one of signal-transducer-effector involved in the subsequent
induction of oxidative stress originating within its mitochondria that
dictates the opening of the mitochondrial permeability transition pore
(Shahbaz et al., 2010). The exaggerated expression of PPAR-α in EPA
plus ET-1 groupmay indicate the presence of a physiological compensa-
tory response under the current experimental setting. Indeed, ET-1
activates not only vaso-constrictive, pro-inﬂammatory and proliferative
factors in the cardiomyocytes, but also cardioprotective factors, includ-
ing ANP and BNP (Fujisaki et al., 1995). Liang et al. suggest that PPAR-αligands could prove to be useful in the management of disorders
associated with hypertrophy and remodeling of the myocardium via
regulating BNP transcription activity (Liang et al., 2003). It is possible
that such a compensatory system, working together with PPAR-α,
may take place in the cardiomyocytes of ET-1-induced hypertrophy
that are pre-treated with EPA. However, future studies are needed to
adequately address this issue.
Here, we also found that the reversing effects of PPAR-α siRNA on
EPA-induced reduction of cardiomyocyte size (surface area) are only
partial (approximately 50%) (Fig. 3B). Such ﬁndings are comparable to
EPA's action on ET-1-induced increase in cell size. These outcomes
indicate that such a regulation may involve other ET-1-dependent
mechanisms, consistent with our earlier comments expressing our
surprise on data showing that EPA solely stimulates PPAR-α, an effect
blocked by ET1 (Fig. 1), whereas both potentiate expression of PPAR-
α. Previously, we have also shown that that EPA inhibits the important
hypertrophic pathway involving TGF-β1, JNK and c-Jun in ET-1-induced
hypertrophied cardiomyocytes (Shimojo et al., 2006). Kitamura et al
showed that treatment with EPA attenuated atrial ﬁbrosis, ERK
phosphorylation, and TGF-β1 expression of atrium in a rabbit model
of atrial ﬁbrillation (Kitamura et al., 2011). Furthermore, rats fed the
5% n-3 PUFA, including EPA diet had lower enterocytic phosphorylated
JNK protein and secreted less cholesterol into the mesenteric lymph
compared with the control (Lu et al., 2011). In addition, the work by
Fujisaki (Fujisaki et al., 1995), who demonstrated an ET1-ETAmediated
autocrine loop (positive feedback) maintaining cell growth in cardiac
ﬁbroblasts, may also explain for the partial attenuation of EPA
exerted antihypertrophic effect by PPAR-α siRNA on ET-1 induced
hypertrophied cardiomyocytes. Collectively, these data imply the
existence of other mechanisms of anti-hypertrophic effects of EPA on
ET-1-induced hypertrophied cardiomyocyte.
There are some obvious limitations in this study besides the
limitations already stated above. First, the present study only utilized
the cardiomyocyte culture. Future studies should also use non-
cardiomyocytes (ﬁbroblast, endothelial cell, smooth muscle cell etc.),
either alone (pure) or co-cultured. It is likely that different cells, alone
or co-cultured may generate ﬁndings that are different from the
current study. In addition, there is also a need to replicate the current
experiment in vivo.
Conclusion
In conclusion, the present study shows that ET-1 induces signiﬁcant
cardiomyocyte hypertrophy, and that pretreatmentwith EPA attenuated
these remodeling events by up regulating levels of PPAR-α pathway.
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